Literature DB >> 22326982

Identifying worsening surgical site infection performance: control charts versus risk-adjusted rate outlier status.

Elise H Lawson1, Bruce Lee Hall, Nestor F Esnaola, Clifford Y Ko.   

Abstract

Control charts are used in industry to monitor performance and are being used increasingly in hospitals as a quality improvement tool. The authors' objective was to determine if control charts using surgical site infection (SSI) rates predict changes in outlier status for risk-adjusted SSI rates using data from a surgical registry, the American College of Surgeons National Surgical Quality Improvement Program. Control charts of monthly SSI rates for 100 hospitals were analyzed for indicators of a performance change in 2009 (vs 2008) using standard rules. Hospitals also were classified as having better, worse, or no change in outlier status for risk-adjusted SSI rates in 2009 (vs 2008). There was moderate agreement between these methods (weighted κ = 0.401). Control charts predicted nonworsening performance well (specificity = 92.9%) and identified changes in SSI performance sooner; however, they failed to identify 31.2% of hospitals with worsened outlier status. This study demonstrates that these quality measurement tools have unique strengths and weaknesses and are complementary uses of the same clinical data source.

Mesh:

Year:  2012        PMID: 22326982     DOI: 10.1177/1062860611428760

Source DB:  PubMed          Journal:  Am J Med Qual        ISSN: 1062-8606            Impact factor:   1.852


  2 in total

1.  Preparatory Time-Related Hand Surgery Operating Room Inefficiency: A Systems Analysis.

Authors:  Michael T Milone; Heero Hacquebord; Louis W Catalano; Steven Z Glickel; Jacques H Hacquebord
Journal:  Hand (N Y)       Date:  2019-02-27

2.  Monitoring scheme for early detection of coronavirus and other respiratory virus outbreaks.

Authors:  Salah Haridy; Ahmed Maged; Arthur W Baker; Mohammad Shamsuzzaman; Hamdi Bashir; Min Xie
Journal:  Comput Ind Eng       Date:  2021-03-16       Impact factor: 5.431

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.